Woodline Partners LP Has $6.48 Million Stock Holdings in MBX Biosciences, Inc. $MBX

Key Points

• Woodline Partners LP increased its stake in MBX Biosciences, Inc. by 44.1%, now holding approximately $6.48 million worth of shares.
• MBX Biosciences received favorable ratings from multiple analysts, including an "outperform" rating and a price target of $38.00.
• The company's stock is currently trading around $10.83, significantly below its 52-week high of $27.50.

Woodline Partners LP boosted its holdings in shares of MBX Biosciences, Inc. (NYSE:MBX - Free Report) by 44.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 877,461 shares of the company's stock after purchasing an additional 268,740 shares during the period. Woodline Partners LP owned approximately 2.63% of MBX Biosciences worth $6,476,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. BNP Paribas Financial Markets acquired a new stake in MBX Biosciences during the fourth quarter valued at approximately $27,000. New York State Common Retirement Fund acquired a new stake in MBX Biosciences during the first quarter valued at approximately $32,000. Deutsche Bank AG lifted its stake in MBX Biosciences by 102.0% during the first quarter. Deutsche Bank AG now owns 8,762 shares of the company's stock valued at $65,000 after purchasing an additional 4,424 shares during the last quarter. Wealthedge Investment Advisors LLC acquired a new stake in MBX Biosciences during the first quarter valued at approximately $88,000. Finally, Nuveen LLC acquired a new stake in MBX Biosciences during the first quarter valued at approximately $107,000.

Wall Street Analysts Forecast Growth

Several analysts recently commented on MBX shares. Oppenheimer started coverage on shares of MBX Biosciences in a research note on Wednesday, July 16th. They set an "outperform" rating and a $38.00 target price for the company. Mizuho began coverage on shares of MBX Biosciences in a research note on Tuesday, August 5th. They set an "outperform" rating and a $38.00 target price for the company. Eight analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $37.63.

MBX Biosciences Stock Up 0.4%

Shares of MBX stock traded up $0.04 during trading hours on Monday, reaching $10.87. 392,315 shares of the stock traded hands, compared to its average volume of 330,141. MBX Biosciences, Inc. has a 1-year low of $4.81 and a 1-year high of $27.50. The business has a fifty day moving average price of $13.05 and a 200 day moving average price of $11.00. The firm has a market capitalization of $365.17 million and a PE ratio of -2.39.

About MBX Biosciences

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.